GU Cancers Symposium 2014 - NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer - Poster


SAN FRANCISCO, CA USA ( - Presented by Dean F. Bajorin, Padmanee Sharma, Leonard G. Gomella, Elizabeth R. Plimack, Peter H. O'Donnell, Jean H. Hoffman-Censits, Thomas W. Flaig, David I. Quinn, Robert Brownell Sims, Michael Locker, Nadeem A. Sheikh, Todd DeVries, and Seth P. Lerner at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 NeuAct DN24 02 Abstract-296 poster thumb

Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX; Jefferson Medical College and Kimmel Cancer Center, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; The University of Chicago, Chicago, IL; University of Colorado, Denver, CO; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Dendreon Corporation, Seattle, WA; Baylor College of Medicine, Houston, TX